Back to top

Image: Bigstock

How Will Limbach's (LMB) Top Line Shape Up in Q3 Earnings?

Read MoreHide Full Article

Limbach Holdings, Inc. (LMB - Free Report) will report third-quarter 2020 results on Nov 12 after the bell.

The company’s top-line performance in the to-be-reported quarter is expected to have been weak due to adverse impacts of the pandemic on field activity. The Zacks Consensus Estimate for revenues is pegged at $142 million, indicating a decline of 3.9% from the year-ago quarter’s reported figure.

Revenue weakness in Florida, Eastern and Western Pennsylvania, and New England regions due to project suspensions are anticipated to have weighed on the construction segment revenues. Michigan, Ohio, and Southern California operating regions are expected to have performed well. Service revenues are expected to have been negatively impacted due to pandemic-led delays in a number of operating regions.

Limbach’s revenues grew a modest 1.9% to 135.2 million year over year in the second quarter of 2020 amid pandemic-induced project suspensions and delays in several of its operating regions.

Limbach currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Recent Performance Some Business Services Companies

Equifax Inc. (EFX - Free Report) reported third-quarter 2020 adjusted earnings of $1.87 per share that beat the Zacks Consensus Estimate by 16.2% and improved 26.4% on a year-over-year basis. Revenues of $1.07 billion outpaced the consensus estimate by 5.9% and improved 22% year over year.

ManpowerGroup Inc. (MAN - Free Report)  reported third-quarter 2020 earnings of $1.12 per share, beating the consensus mark by 90.5% but declining more than 37.5% year over year. Revenues of $4.58 billion surpassed the consensus mark by 8.7% but declined 12.7% year over year.

IHS Markit Ltd. (INFO - Free Report) recorded third-quarter fiscal 2020 adjusted earnings per share of 77 cents that surpassed the consensus estimate by 11.6% and increased 15% on a year-over-year basis. Total revenues came in at $1.07 billion, marginally surpassing the consensus mark but declining 4% from the year-ago quarter.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Published in